Holen Sie sich die Stockscreener-App
1.79
1.65%
-0.03
Handel nachbörslich:
1.83
0.04
+2.23%
Schlusskurs vom Vortag:
$1.82
Offen:
$1.87
24-Stunden-Volumen:
968.34K
Relative Volume:
2.17
Marktkapitalisierung:
$142.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.65M
KGV:
-5.0983
EPS:
-0.3511
Netto-Cashflow:
$-15.84M
1W Leistung:
-8.67%
1M Leistung:
-6.77%
6M Leistung:
-17.51%
1J Leistung:
+112.61%
1-Tages-Spanne:
$1.69
$1.92
1-Wochen-Bereich:
$1.69
$1.9801
52-Wochen-Spanne:
$0.7912
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Vergleichen Sie CRDL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CRDL | 1.79 | 142.46M | 0 | -21.65M | -15.84M | -0.3511 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy - Proactive Investors USA
Cardiol's CardiolRx Shows Major Pain Relief Success in Phase II Pericarditis Trial | CRDL Stock News - StockTitan
Cardiol Therapeutics Faces Rising Losses and Falling Assets - TipRanks
Wealth Enhancement Advisory Services LLC Takes $27,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
"Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors" - WICZ
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors” - The Globe and Mail
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - Investing News Network
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Down 3.9% – Here’s What Happened - Defense World
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN - The Globe and Mail
Biotech and Technology Giants Drive Innovation Across Pharma, Me - WICZ
Cardiol Therapeutics (TSX:CRDL) Shares Outstanding (EOP) : 69.32 Mil (As of Jun. 2024) - GuruFocus.com
MMCAP International Inc. SPC Acquires Shares in Cardiol Therapeu - GuruFocus.com
Comparing Cardiol Therapeutics (NASDAQ:CRDL) and IN8bio (NASDAQ:INAB) - Defense World
Net Present Value Model: Cardiol Therapeutics Inc’s Cannabidiol 1 - GlobalData
Top 4 Canadian Biotech Stocks of 2024 - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Shares Down 0.8% – Should You Sell? - Defense World
Cardiol Therapeutics (TSE:CRDL) Trading Down 0.8%Should You Sell? - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Increase in Short Interest - MarketBeat
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail
Equities Analysts Set Expectations for CRDL Q3 Earnings - MarketBeat
HC Wainwright Issues Negative Outlook for CRDL Earnings - Defense World
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Shares Acquired by Foundations Investment Advisors LLC - Defense World
HC Wainwright Reiterates "Buy" Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
H.C. Wainwright maintains Buy rating on Cardiol Therapeutics shares By Investing.com - Investing.com UK
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? - MSN
Cardiol Therapeutics advances CardiolRx in new trial By Investing.com - Investing.com Australia
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX - openPR
Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx Trademark - openPR
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside… - Barchart
Cardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trial - Proactive Investors Australia
Cardiol Therapeutics advances CardiolRx in new trial - Investing.com
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis - Newsfile
Troutman Pepper Advises Cardiol Therapeutics in Closing of Over-Allotment Option - Troutman Pepper
BPH Global Ltd (ASX: BP8) – Trading Halt - Investing News Network
Cardiol Therapeutics (FRA:CT9) Operating Cash Flow per Shar - GuruFocus.com
Gold SPDR (GLD-A) QuotePress Release - The Globe and Mail
Deeper Dive: Understanding Cardiol Therapeutics Inc (CRDL) Through its Various Ratios - The Dwinnex
Cardiol Therapeutics raises $15.5M following over-allotment option exercise - Proactive Investors USA
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option - Yahoo Finance
Cardiol Therapeutics Inc [CRDL] is 117.03% higher this YTD. Is it still time to buy? - The DBT News
Get in on Cardiol Therapeutics Inc’s (CRDL) buy-in window today! - SETE News
Cardiol Therapeutics closes $13.5M offering - Proactive Investors USA
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares - StockTitan
Cardiol Therapeutics Secures $13.5M in Public Offering - TipRanks
CRDL’s 2023 Market Dance: Up 90.31% – Time to Invest? - The InvestChronicle
Examining CRDL’s book value per share for the latest quarter - US Post News
Cardiol Therapeutics (TSE:CRDL) Trading Down 19.7%Here's What Happened - MarketBeat
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today - Benzinga
Cardiol Therapeutics prices $13.5M public offering - Proactive financial news
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares - Investing News Network
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):